20 May, 2024 - Press Release
Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses, marks a significant milestone with the shipment of its first set of R21/Matrix-M™ malaria vaccine to Africa....Read more
03 May, 2024 - Press Release
The collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatment for non-muscle invasive bladder cancer. SII will manufacture both standard BCG (“sBCG”) & next-generation recombinant BCG (“iBCG”), creating a long-term solution to chronic BCG supply shortage issues....Read more
25 April, 2024
On World Malaria Day, the architects behind the R21/Matrix-M vaccine present their take on the road ahead....Read more
16 April, 2024 - Press Release
Serum Institute of India Pvt. Ltd (SIIPL), in collaboration with the University of Oxford, is developing a novel solution for Men-B disease, advancing global accessibility to life-saving vaccines. This partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine....Read more
12 April, 2024 - Press Release
In a landmark collaboration announced today, Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalised cancer care. This partnership aims to bring cutting edge treatment options within reach of millions globally...Read more
02 October, 2023 - Press Release
The R21/Matrix-M™ malaria vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, has been recommended for use by the World Health Organization (WHO) after meeting required safety, quality and effectiveness standards.Read more
06 July, 2023
Hon'ble UK Minister of State; Science, Technology & Innovation, George Freeman and UK Trade Commissioner for South Asia, Harjinder Kang along with members of the UK Trade Commission visit Serum Institute Of India and meet with SII CEO Adar Poonawalla and Chairman Dr. Cyrus Poonawalla.Read more
17 December, 2021 - Press Release
World Health Organization (WHO) has granted Emergency Use Listing (EUL) for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine 'COVOVAX™' with Matrix-M™ adjuvant, for active immunization of individuals 18 years of age and older.... Read more
15 December, 2021
The Poonawalla Vaccines Research Building is to be established at Oxford University following £50m funding commitment from Serum Life Sciences Ltd., a subsidiary of Serum Institute of India Pvt. Ltd.... Read more
22 September, 2021
Serum Life Sciences Ltd announces a strategic partnership with Oxford Biomedica, with the objective of building long term capacity in the UK.... Read more
16 March, 2021 - BBC HARDtalk
Adar Poonawalla went all-in on a coronavirus vaccine production deal with Astrazeneca, can he make enough to supply the world?.... Read more
03 March 2021 - The Economist
By the end of the year, Mr Poonawalla says, it will add 1.5bn covid-19 shots to 1.3bn-1.5bn doses against diseases from measles to tuberculosis that it already produces annually.... Read more
28 February, 2021 - BBC News
As pharmaceutical giants ramp up production in the race to vaccinate the world, one firm has shot into the lead.... Read more
14 February 2021 - The Guardian
Adar Poonawalla, chief executive of the Serum Institute of India, on vaccines, regulation and what comes next.... Read more
12 January, 2021
'An emotional moment for the team at @SerumInstIndia as the first shipments of COVISHIELD finally leave for multiple locations across India',.... Read more
23 December, 2020
Serum Institute of India (SIIPL) has partnered with Dynavax Technologies Corporation a biopharmaceutical company focused on developing.... Read more
14 December, 2020
Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial.... Read more
11 November 2020 - Washington Post
Adar Poonawalla is an Indian billionaire whose family-owned firm makes more vaccines a year than any other company on Earth. Ask him about the race for a coronavirus vaccine and he will offer some unvarnished opinions.... Read more
29 September, 2020
A further collaboration amongst the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate.... Read more
22 September, 2020
Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against Covid-19.... View Part 1
22 September, 2020
Adar Poonawalla explains the timing, challenges & cost of vaccinating the world against Covid-19....View Part 2
16 September, 2020
Novavax, Inc. announced an amendment to its existing agreement....Read more
08 September, 2020
SpyBiotech has signed an exclusive global licensing agreement with Serum Institute of India for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19....Read more
11 August, 2020
The Serum Institute of India is preparing to crank out a billion doses. And that's just the beginning....Read more
7 August, 2020
The Bill & Melinda Gates Foundation said it is backing the world’s largest vaccine maker....Read more
7 August, 2020
Geneva, 7 August 2020 – A new landmark collaboration between SII....Read more
6 August, 2020
Novavax, Inc. announced a license agreement with Serum Institute of India for the development and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in low- and middle-income countries (LMIC) and India.... Read more
01 August 2020 - The New York Times
The world’s largest vaccine producer, the Serum Institute, announced a plan to make hundreds of millions of doses of an unproven inoculation....Read more
16 July 2020 - Politico
Adar Poonawalla is seizing on the COVID-19 fight to try to break down the policies protecting Big Pharma....Read more
04 June, 2020
Poonawalla is betting big on a Covid-19 vaccine, and preparing for the next possible pandemic....Read more